Scleroderma Associated Antibody (Scl-70), IgG
Scleroderma is a collagen-vascular disease of unknown etiology; it assumes various clinical forms including localized and diffuse forms. It occurs in all races and is three times more likely in women. Symptoms that are initially associated with the disease usually appear in the third decade of life. Development of the disease has been associated with several occupations and also as drug-induced. Scleroderma associated antibody, or Scl-70, is an epitope (antigen) present in the DNA topoisomerase 1 protein. DNA topoisomerase is a nuclear protein responsible for nicking and uncoiling DNA during gene transcription and/or repairing process.
Progressive systemic sclerosis (PSS) is the diffuse form of scleroderma; it is a multisystem disease with marked sclerosis of skin, gastrointestinal tract, lungs, vessels, heart, and kidneys. A correlation between T-cell hyperactivity and disease activity is usually seen. There is evidence suggesting the increased collagen production in the disease is due to activated T-cells. In addition to these antibodies, patients with skin and internal organ disease also develop an antibody to centromere proteins (proteins binding a region of DNA typically found near the middle of a chromosome). Both antibodies are useful for differential diagnosis of scleroderma from other mixed connective diseases such as eosinophilic fasciitis, scleromyxedema as well as CREST syndrome. Up to 60% of scleroderma patients have autoantibody to Scl-70 when done by EIA. In addition, most patients with scleroderma (>70%) have a positive ANA. Therefore, in addition to Scl-70, other ANA disease-related auto-antibodies should be ordered. Positivity for anti-scl 70 confers an increased risk of interstitial pulmonary fibrosis and is considered an unfavorable prognostic sign.
- Diagnostically useful in the differential diagnosis of diffuse scleroderma
- The test has prognostic significance for severe digital ischemia in patients with Raynaud disease and scleroderma
- As an aid in diagnosis of other autoimmune diseases
Increased in:
- Scleroderma (25–40% sensitivity, high specificity)
- Might be postive in some other autoimmune diseases
Note: Absence of scleroderma antibody does not exclude diagnosis either of Primary Sjögren syndrome or of CREST (CREST acronym = calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome.
Predictive value of a positive test is >95% for scleroderma.
Reference ranges and specimen collection vary from test method and laboratories performing this test. To properly evaluate your test results, consult with the ordering physician or healthcare provider. For more information about thsi test, please refer to listed references.
Negative (Non-reactive)
Weakly positive results for anti-Scl 70 antibodies may occur in sera with high levels of anti-dsDNA antibodies when tests are performed by EIA methods.
Serum (SST).
Stability
- Ambient: 5-7 days
- Refrigerated: 7-14 days
- Frozen: 60 days
- Am J Med. 1997 Sep;103(3):242-8. [PMID: 9316557]
- Autoimmunity. 2005 Feb;38(1):65-72. [PMID: 15804707]
- Am Fam Physician. 2002;65:1073. [PMID: 11925083]
- Dermatology. 2002;204:29. [PMID: 11834846]
- Ann N Y Acad Sci. 2005;1050:217. [PMID: 16014537]
- Clin Exp Rheumatol. 1989 Sep-Oct;7 Suppl 3:S57-62 [PMID: 269116]
- Jacobs DS and DeMott WR. Laboratory Test Handbook. 5th. Hudson, OH. Lexi-Comp, Inc (2001).